HLB Pharmaceutical Co. Ltd (047920) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.86 Billion ≈ $1.26 Million USD) by net assets (₩120.95 Billion ≈ $81.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of HLB Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.
HLB Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how HLB Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of HLB Pharmaceutical Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
HLB Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.053x |
|
Orient Group Inc
SHG:600811
|
0.011x |
|
STILLFRONT GRP AB SK-07
F:1YS0
|
0.110x |
|
Josef Manner & Comp. AG
VI:MAN
|
-0.119x |
|
Anhui Provincial Architectural Design and Research Institute Co.Ltd.
SHE:301167
|
N/A |
|
Zeng Hsing Industrial Co Ltd
TW:1558
|
0.031x |
|
DIRECTA SIM SPA
F:ZP7
|
N/A |
|
Shalby Limited
NSE:SHALBY
|
0.014x |
Annual Cash Flow Conversion Efficiency for HLB Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of HLB Pharmaceutical Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 047920 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩116.40 Billion ≈ $78.88 Million |
₩6.84 Billion ≈ $4.64 Million |
0.059x | +128.28% |
| 2023-12-31 | ₩88.15 Billion ≈ $59.74 Million |
₩-18.32 Billion ≈ $-12.41 Million |
-0.208x | -546.24% |
| 2022-12-31 | ₩85.93 Billion ≈ $58.23 Million |
₩-2.76 Billion ≈ $-1.87 Million |
-0.032x | -90.74% |
| 2021-12-31 | ₩78.38 Billion ≈ $53.12 Million |
₩-1.32 Billion ≈ $-895.45K |
-0.017x | -86.48% |
| 2020-12-31 | ₩44.62 Billion ≈ $30.24 Million |
₩-403.36 Million ≈ $-273.35K |
-0.009x | -111.60% |
| 2019-12-31 | ₩17.36 Billion ≈ $11.76 Million |
₩1.35 Billion ≈ $917.12K |
0.078x | +174.56% |
| 2018-12-31 | ₩17.00 Billion ≈ $11.52 Million |
₩-1.78 Billion ≈ $-1.20 Million |
-0.105x | -124.00% |
| 2017-12-31 | ₩16.80 Billion ≈ $11.39 Million |
₩-784.30 Million ≈ $-531.51K |
-0.047x | -313.95% |
| 2016-12-31 | ₩18.90 Billion ≈ $12.81 Million |
₩-213.11 Million ≈ $-144.42K |
-0.011x | +82.16% |
| 2015-12-31 | ₩12.18 Billion ≈ $8.25 Million |
₩-769.59 Million ≈ $-521.54K |
-0.063x | -119.72% |
| 2014-12-31 | ₩4.81 Billion ≈ $3.26 Million |
₩1.54 Billion ≈ $1.05 Million |
0.320x | -- |
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more